Navigation Links
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Date:11/26/2007

Following FDA Approval, Agreement will Broaden Access to

Cholesterol-Reducing Medicine

PHILADELPHIA and WHITEHOUSE STATION, N.J., Nov. 26 /PRNewswire/ -- GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR(R) (lovastatin). Under the agreement, GSK will have exclusive rights to market non-prescription MEVACOR in the United States. Terms of the agreement are confidential but include milestone and royalty payments from GSK to Merck.

MEVACOR was introduced in the United States in 1987 by Merck as the first in a class of cholesterol-reducing medicines known as "statins". The U.S. patent for MEVACOR expired in 2001.

Commenting on the agreement, JP Garnier, chief executive officer, GlaxoSmithKline said, "This new partnership with Merck will enable GSK to address the important public health issue of high cholesterol and help patients better manage their health. OTC Mevacor will be a dynamic new addition to our fast-growing over-the-counter business and is further evidence of GSK's ability to partner in new OTC switch opportunities."

"With MEVACOR, Merck pioneered the development of cholesterol-lowering medicines known as "statins" which are recognized worldwide and remain the standard of care today," said Richard T. Clark, chief executive officer, Merck. "We are pleased to be able to partner with GSK as a way to bring MEVACOR directly to consumers in the United States."

Application for OTC MEVACOR to be reviewed by FDA

The new drug application (NDA) for OTC MEVACOR will be reviewed by the U.S. Food and Drug Administration (FDA) in a joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) on December 13. The NDA, filed by Merck, is seeking approval of
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... As reported by Wood TV 8 in the ... has seen a nearly 500-person increase in heroin related overdose ... 271 between 1999 and 2002, the toll increased to 728 ... other states, drug users in Michigan have turned to heroin ... compared the price of both substances, noting that an 80-milligram ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- The human brain can ... dehydration, a new study finds. Although dehydration ... England have found that the brain compensates by increasing ... "This research has helped us understand a lot ... exercise in extreme conditions," study first author Steven Trangmar, ...
(Date:7/25/2014)... 25, 2014 Ticket Down is ... Milan tickets in Berkeley at California Memorial Stadium. With ... fans of football, the organizers of the 2014 Guinness International ... teams to North America. With teams representing La Liga, English ... bring some of the best football players from around the ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 This ... current state of the Galactooligosaccharides (GOS) industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:7/25/2014)... Babies seem to learn even before they,re born, a ... 34 weeks pregnant, their unborn babies can respond to ... nursery rhyme, the researchers report. "The mother,s voice ... developing fetus," Charlene Krueger, nursing researcher and associate professor ... in a university news release. "This research highlights just ...
Breaking Medicine News(10 mins):Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2
... Quigley,Corporation (Nasdaq: QGLY ) today reported net sales ... ended March 31, 2008,compared to $6.1 million reported for ... of 2008 reflects a net sales decrease for the,Company,s ... first quarter,of 2007. The change during 2008 as compared ...
... Company to Host Conference Call at 4:30 p.m. EDT Today ... PCYC ) today reported financial results for its third fiscal,quarter ... quarter of fiscal,2008 was $7.0 million, or $0.27 per share, ... share, in the third quarter of fiscal 2007., Total ...
... Actavis Group, the,international generic pharmaceuticals company, today ... study on the Company and its President,and CEO. ... was presented in an MBA class in international ... made available to business,schools around the world., ...
... Act on Capitol Hill, WASHINGTON, April 24 ... and questions for the patient, their families and,caregivers. ... cancer care by affording the patient the opportunity ... thought the cancer diagnosis, treatment,and follow up care., ...
... April 24 The Asthma and Allergy,Foundation of America ... today -- the most challenging places to live for ... year for many allergy,sufferers from Lexington, KY (ranked #1), ... Allergy Capitals based on the impact that key,environmental and ...
... Association urges Senators Boxer and Feinstein to quickly pass,companion ... April 23 AARP thanked,the supporters and cosponsors of ... passed today in the U.S. House of Representatives. The ... by stopping,harmful cuts proposed by the administration., "Today,s ...
Cached Medicine News:Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 2Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 3Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 4Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 5Health News:Pharmacyclics Reports Third Quarter 2008 Financial Results 2Health News:Pharmacyclics Reports Third Quarter 2008 Financial Results 3Health News:Pharmacyclics Reports Third Quarter 2008 Financial Results 4Health News:Pharmacyclics Reports Third Quarter 2008 Financial Results 5Health News:Pharmacyclics Reports Third Quarter 2008 Financial Results 6Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 2Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 3Health News:Support for Patient Navigation Services to Help Cancer Patients 2Health News:2008 Spring Allergy Capitals Announced 2Health News:AARP Thanks California's Representatives for Supporting Bill to Protect People in Medicaid 2
(Date:7/25/2014)... , July 25, 2014  Depomed, Inc. (NASDAQ: ... second quarter fiscal year 2014 financial results after the ... host a conference call beginning at 4:30 pm EDT, 1:30 ... access the call by dialing 877-317-6789 ( United ... will also be available via a live webcast on ...
(Date:7/25/2014)... LAS VEGAS , July 25, 2014 GrowBLOX ... of a binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, ... to pursue the acquisition of both cultivation and dispensary medical ... . Pursuant to the MOU, GBLX will acquire a 20% ... use our proprietary GrowBLOX TM growing chambers, as well ...
(Date:7/25/2014)... ALBANY, New York , July 25, 2014 /PRNewswire/ ... published by Transparency Market Research "Global and China Insulin ... Insulin) - Industry Analysis, Size, Share, Growth, Trends and ... insulin market was valued at USD 19.99 billion in ... of 6.1% from 2013 to 2019 to reach USD ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... CVS Caremark Corporation (NYSE: CVS ) today announced that Tom Ryan , Chairman, President and CEO, ... to investors at the Barclays Capital 2010 Global Healthcare Conference on March 23, 2010 . The Company is ... ... , ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended ... ... ... ...
Cached Medicine Technology:CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 2CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 7BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 9BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 10BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 11BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 12BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 13
Stainless steel dull finish....
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
Medicine Products: